Goodland Pharma’s Post

Altamira Therapeutics aims to provide hope for those suffering from #RheumatoidArthritis with AM-411, our intravenously administered nanoparticle based on the OligoPhore™ platform. AM-411 targets p65, one of the main transcriptional regulators of the NF-kB pathway and a key checkpoint in #RA inflammation. What makes AM-411 different? - Precise targeting: AM-411 goes straight to the source of inflammation, leaving healthy tissues untouched. This could mean fewer side effects compared to current treatments. - Durable effect: By reducing p65 production, AM-411 aims to break the cycle of inflammation and offer longer-lasting relief. - Novel approach: This new RNA-based technology holds promise for tackling other inflammatory diseases beyond RA. Discover more: https://bit.ly/3JjIBix #Science #RNADelivery #siRNA #mRNA #RNATherapeutics

🔔 First clinical evaluation of an inhaled mRNA-based therapy designed to restore ciliary function in people with PCD ! 👏 ReCode Therapeutics’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) delivery platform was used to develop RCT1100, an inhaled mRNA therapy designed to deliver and express DNAI1 mRNA in target cells. 🔎 Interested in monitoring mRNA therapeutic related IP like recently published patent related to SORT LNP? Take advantage of KnowMade's patent monitoring service that is focused on therapeutic mRNA https://lnkd.in/eCfnR-ct #mrna #LNP #patent #innovation

Don’t miss the opportunity to connect with our CEO Anker Lundemose at #BioEquity Europe 2024, from 12 - 14 May in San Sebastian, Spain! It’s an ideal time to meet as the clinical trial for our lead asset #MTX325 is now underway. MTX325, is a potentially disease-modifying treatment for #Parkinsons Disease, a progressive neurological condition that affects over 10 million people worldwide. 📧 Hear the latest developments on Mission Therapeutics’ innovative #mitophagy targeting pipeline in a 1-1 meeting using the link in the comments below. @Mission Therapeutics is committed to advancing its pipeline of deubiquitylating enzyme (#DUBs) inhibitor drug candidates for conditions driven by a build-up of dysfunctional mitochondria in cells, including #ParkinsonsDisease, #HeartFailure, #KidneyDisease, #DuchennesMuscularDystrophy (#DMD), #idiopathicpulmonaryfibrosis (#IPF) and #Alzheimers. #BioEquityEurope #BioEquity2024

#ASLTreatment - Motor Neuron Disease - recent scientific research showed that Allogeneic B cell immunomodulatory therapy benefitted lab models, i.e. laboratory animals. As a result, the researches got permission from the FDA and Massachusetts General Hospital to try this therapeutic approach in an individual w/ #ALS. There are a range of alternative approaches to developing ALS therapies. We particularly like MSCs including $BCLI's NurOwn, its P3b trial has just begun rollout - of course $BCLI needs further funding to complete, but it is an interesting area with some promise of marked progress in therapy effectiveness for early to mid-stage ALS sufferers, if BCLI's P3b is a success. To see where $BCLI is right now you can read our #ACFResearch #NurOwn Update https://lnkd.in/dFgfxHpk $AZN $AMGN $SNY $GILD $VRTX $ABBV $AMRX $ROG.SW $MRK $PFE $TEVA $NVS $BIIB. Brainstorm Cell Therapeutics Pfizer AbbVie ALS TDI The ALS Association ALS CURE Project

The PHARMO Institute and Lumanity are partnering to deliver research insights into amyloidosis and its hard-to-identify subtypes, such as light chain (AL), amyloid (AA), and transthyretin amyloidosis (ATTR), and we invite you to put our data to the test. Our data is well-suited/ ready for conducting amyloidosis research with: - >10,000 patients with an amyloidosis related hospital admission or ambulatory consultation - Unique linkages to clinical labs and pathology data to uncover specific blood-based test results, biopsy, and gene sequences that point to clinical subtypes - Ability to address a range of RWE use cases from drug safety, treatment patterns, comparativeness effectives, clinical outcomes, and beyond Learn more about our expertise in Amyloidosis at https://buff.ly/42UVVlZ and contact us to discuss your research needs in amyloidosis. #amyloidosis #amyloidosisresearch #RWE #realworldevidence #drugsafety #ATTR

#StemCells Oral #ALStherapy by #TransposonTherapeutics (TPN-101 PIIa trial) shows safety & slows lung function decline over w/ 1yr’s treatment in ALS C9orf72 mutations. Also see NurOwn PIIIb - Read our #ACFResearch update on $BCLI https://lnkd.in/e2sThM9S The ALS Association ALS TDI

Increased awareness and collaboration are key to innovation. Orphan drug innovation has gone from strength to strength, propelled by advances in genetic medicine, such as mRNA therapies. However, challenges remain. In this article, Will Maier, VP and Head of Centre for Rare Disease, ICON Biotech, explores the challenges and the necessary solutions to advance rare disease drug development in today’s dynamic landscape. Read it now: https://ow.ly/9gmi50RxcJ1. #RareDisease #OrphanDrug #DrugDevelopment #HealthcareInnovation #RareDiseaseAwareness

Increased awareness and collaboration are key to innovation. Orphan drug innovation has gone from strength to strength, propelled by advances in genetic medicine, such as mRNA therapies. However, challenges remain. In this article, Will Maier, VP and Head of Centre for Rare Disease, ICON Biotech, explores the challenges and the necessary solutions to advance rare disease drug development in today’s dynamic landscape. Read it now: https://ow.ly/bIw950RvYXm. #RareDisease #OrphanDrug #DrugDevelopment #HealthcareInnovation #RareDiseaseAwareness

Introducing Hornet Therapeutics: Pioneering Treatment for EBV-Driven Diseases 🚀 Exciting news for Hornet Therapeutics, as they emerge from stealth mode with groundbreaking data published in Science! 📰 This marks a significant milestone in the fight against Epstein-Barr Virus (EBV) and its related diseases. 🔑Key Highlights🔑 🐝 Revolutionary Treatment: First-ever small molecule drug for EBV-driven diseases. 🐝 Published Data: Demonstrates decreased EBV latency with IDO-1 inhibition. 🐝 Strategic Partnership: Collaboration with Kyowa Kirin. 🐝 Clinical Trials Ahead: Proof-of-concept studies for EBV-driven PTLD in transplant patients. 🌟 What Makes the Lead Asset (HTX-201) & This Antiviral Approach Significant? 🌟 👉 Addresses a significant unmet need in solid organ transplant populations. 👉 Broad Potential: Future targets include Multiple Sclerosis, Mononucleosis, and long-COVID. #Biotech #MedicalInnovation #EBV #HealthTech #Science #Transplantation #MS #LongCOVID #AntiviralTherapy #Healthcare

INDUSTRY NEWS - CAR-T in autoimmunity My thoughts on the news 'Cartesian Therapeutics clears an autoimmune CAR-T trial, starts another Phase 2 and raises $130M' https://lnkd.in/eHtpW7T3 This is an exciting development that expands on tantalizing CAR-T data in autoimmunity first reported in lupus last year. Is autoimmunity the saving grace for the CAR-T field as multiple companies migrate from oncology? The competition will be no less fierce in autoimmunity where mAbs have made significant advances over the years and are truly off-the-shelf products, and cheaper as well. One key question concerns how many CAR-T products can the autoimmunity field accommodate, especially if they are all targeting B cell specific antigens. Perhaps the competitive landscape will be adjudicated by the relative durability of any response. Whereas the durability of mAb function is dictated by standard pharmacokinetics, the durability of CAR-T responses may be longer if they function as an immunomodulatory reset to the immune system. Time and data will tell. #Alloplex #celltherapies #CAR-T #oncologyresearch #cancerresearch